Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
greatest decrease » treatment decreased (Expand Search), greater increase (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
14061
Image 3_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”
-
14062
Table 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”
-
14063
Table 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”
-
14064
Table 4_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”
-
14065
Image 1_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”
-
14066
Image 5_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”
-
14067
Table 1_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”
-
14068
Image 6_PD-1/PD-L1 inhibitors plus bevacizumab plus chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy for advanced non-small cell lung cancer: a phase 3 RCT based meta-an...
Published 2025“…</p>Results<p>Three RCTs (IMpower150, jRCT2080224500, and ORIENT-31) comprising a total of 1529 patients were analyzed. The PIBC regimen significantly improved PFS (hazard ratio [HR]: 0.76 [0.66, 0.87], P < 0.0001), objective response rate (risk ratio [RR]: 1.36 [1.22, 1.51], P < 0.00001), and disease control rate (RR: 1.06 [1.00, 1.12], P = 0.04). …”
-
14069
<b>Efficacy of </b><b>GLP-1-based Therapies on</b><b> </b><b>Metabolic Dysfunction-Associated Steatotic</b><b> Liver Disease and </b><b>Metabolic Dysfunction-Associated</b><b> Stea...
Published 2025“…Overall, GLP-1RAs treatment for a median of 24 weeks demonstrated a significant reduction in LFC by 5.21%, with the retatrutide displaying the most obvious treatment effects. …”
-
14070
Statistical analysis of the AUC measurement.
Published 2025“…The mean AUC decreased in both samples.</p> <p>(TIF)</p>…”
-
14071
Data Sheet 1_Integrated computational and experimental identification of N-[(1H-1,2,4-triazol-3-yl)phenyl]-1-(1H-pyrazolo[3,4-b]pyridin-3-yl)methanamide as a potent and selective T...
Published 2025“…Survival analysis revealed a significant correlation between elevated TIM-3 expression and decreased patient survival. …”
-
14072
<b>Distributed Hydraulic Micro-Cooling (MHD): A Low-Cost, High-Impact Urban Heat Mitigation Strategy</b> / <b>Enfriamiento Hidráulico Micro-Distribuido (MHD): Estrategia Urbana de...
Published 2025“…Large thermal masses such as roofs, asphalt roads, and concrete structures store significant amounts of solar radiation during the day (up to 1200–1600 MJ/m²). …”
-
14073
Raw data for ASV analysis.
Published 2025“…Treatment with live and heat-killed Ln.m significantly reduced BUN and creatinine levels in CKD mice (<i>p</i> < 0.01 and <i>p</i> < 0.05). …”
-
14074
Raw data.
Published 2025“…Treatment with live and heat-killed Ln.m significantly reduced BUN and creatinine levels in CKD mice (<i>p</i> < 0.01 and <i>p</i> < 0.05). …”
-
14075
Timeline for study enrollment.
Published 2024“…</p><p>Conclusions</p><p>Negative COVID-19 experiences were significantly associated with more severe depression and anxiety in Ugandan caregivers, regardless of their children’s malaria status. …”
-
14076
Dataset used in the manuscript.
Published 2024“…</p><p>Conclusions</p><p>Negative COVID-19 experiences were significantly associated with more severe depression and anxiety in Ugandan caregivers, regardless of their children’s malaria status. …”
-
14077
mRNA levels of CASP family markers (A-E), BCL2 family markers (F-H) and other apoptosis-related markers (I-M) in limbal stromal cells (LSCs) and in Aniridia-LSCs (AN-LSCs), after t...
Published 2025“…In LSCs, <i>BCL2</i> mRNA level significantly decreased (p = 0.0102) and <i>CDKN1B</i> level significantly increased using 75 µM CoCl<sub>2</sub> treatment. …”
-
14078
Investigating the Impact of Base Pair Mismatches on Cas13d Cleavage Efficiency Using Molecular Dynamics Simulations
Published 2025“…However, the presence of mismatches significantly undermines the cleavage efficiency of Cas13d to target RNA. …”
-
14079
Cell proliferation of limbal epithelial cells (LECs) after 20-minute treatment with travoprost at concentrations ranging from 0.039 μg/mL to 40 μg/mL, using the ELISA-BrdU (colorim...
Published 2025“…<p>LEC proliferation decreased significantly following treatment with 20 μg/mL and 40 μg/mL concentrations of travoprost (p = 0.029 and p = 0.006, respectively).…”
-
14080